| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stress Disorders, Post-Traumatic | 76 | 2023 | 1506 | 14.950 |
Why?
|
| Substance-Related Disorders | 48 | 2023 | 1241 | 9.420 |
Why?
|
| Veterans | 32 | 2023 | 904 | 8.750 |
Why?
|
| Implosive Therapy | 19 | 2022 | 171 | 7.440 |
Why?
|
| Opioid-Related Disorders | 24 | 2023 | 298 | 7.210 |
Why?
|
| Alcoholism | 29 | 2023 | 1109 | 6.560 |
Why?
|
| Craving | 11 | 2022 | 200 | 3.530 |
Why?
|
| Comorbidity | 31 | 2022 | 1425 | 3.010 |
Why?
|
| Analgesics, Opioid | 14 | 2023 | 498 | 2.830 |
Why?
|
| Stress, Psychological | 20 | 2022 | 824 | 2.820 |
Why?
|
| Oxytocin | 10 | 2023 | 124 | 2.750 |
Why?
|
| Adult | 92 | 2022 | 21375 | 2.110 |
Why?
|
| Prescription Drug Misuse | 5 | 2015 | 35 | 2.010 |
Why?
|
| Patient Dropouts | 4 | 2021 | 98 | 2.010 |
Why?
|
| Hydrocortisone | 16 | 2022 | 291 | 1.980 |
Why?
|
| Humans | 131 | 2023 | 68525 | 1.790 |
Why?
|
| Treatment Outcome | 34 | 2023 | 7028 | 1.760 |
Why?
|
| Female | 98 | 2023 | 38015 | 1.730 |
Why?
|
| Cocaine-Related Disorders | 17 | 2013 | 504 | 1.680 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 14 | 2021 | 151 | 1.630 |
Why?
|
| Male | 89 | 2022 | 37281 | 1.620 |
Why?
|
| Prescription Drugs | 5 | 2015 | 71 | 1.450 |
Why?
|
| Pain | 6 | 2022 | 472 | 1.440 |
Why?
|
| Behavior, Addictive | 9 | 2017 | 317 | 1.430 |
Why?
|
| Acetylcysteine | 5 | 2022 | 296 | 1.360 |
Why?
|
| Combat Disorders | 3 | 2021 | 102 | 1.290 |
Why?
|
| Alcohol Drinking | 9 | 2022 | 805 | 1.280 |
Why?
|
| Heart Rate | 9 | 2019 | 568 | 1.260 |
Why?
|
| Middle Aged | 51 | 2021 | 21119 | 1.250 |
Why?
|
| Sex Factors | 18 | 2020 | 1265 | 1.150 |
Why?
|
| Psychiatry | 3 | 2022 | 112 | 1.150 |
Why?
|
| Psychotherapy | 8 | 2022 | 253 | 1.140 |
Why?
|
| Sex Characteristics | 5 | 2018 | 295 | 1.060 |
Why?
|
| Sleep | 2 | 2020 | 263 | 1.010 |
Why?
|
| Military Personnel | 4 | 2021 | 220 | 1.000 |
Why?
|
| Affective Symptoms | 2 | 2021 | 50 | 0.990 |
Why?
|
| Psychological Techniques | 3 | 2021 | 17 | 0.970 |
Why?
|
| Psychiatric Status Rating Scales | 15 | 2020 | 782 | 0.950 |
Why?
|
| Double-Blind Method | 11 | 2023 | 1737 | 0.950 |
Why?
|
| Sex Offenses | 3 | 2022 | 170 | 0.930 |
Why?
|
| Pain Measurement | 5 | 2019 | 328 | 0.910 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2023 | 20 | 0.890 |
Why?
|
| Young Adult | 21 | 2020 | 5708 | 0.890 |
Why?
|
| Doxazosin | 2 | 2023 | 20 | 0.890 |
Why?
|
| Severity of Illness Index | 13 | 2020 | 1851 | 0.870 |
Why?
|
| Emotions | 8 | 2022 | 244 | 0.860 |
Why?
|
| Cues | 11 | 2021 | 654 | 0.820 |
Why?
|
| Adrenocorticotropic Hormone | 10 | 2011 | 106 | 0.810 |
Why?
|
| Anger | 1 | 2021 | 47 | 0.800 |
Why?
|
| Prescriptions | 3 | 2021 | 28 | 0.760 |
Why?
|
| Pituitary-Adrenal System | 11 | 2022 | 138 | 0.750 |
Why?
|
| Stress, Physiological | 5 | 2009 | 215 | 0.720 |
Why?
|
| Goals | 2 | 2020 | 65 | 0.710 |
Why?
|
| Pilot Projects | 12 | 2022 | 1341 | 0.700 |
Why?
|
| Iraq War, 2003-2011 | 3 | 2017 | 85 | 0.670 |
Why?
|
| Intimate Partner Violence | 2 | 2018 | 58 | 0.670 |
Why?
|
| Behavior Therapy | 2 | 2019 | 297 | 0.660 |
Why?
|
| Hypothalamo-Hypophyseal System | 10 | 2022 | 150 | 0.660 |
Why?
|
| United States | 14 | 2021 | 7335 | 0.640 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2022 | 257 | 0.630 |
Why?
|
| Buprenorphine | 3 | 2015 | 67 | 0.630 |
Why?
|
| Internship and Residency | 2 | 2022 | 596 | 0.610 |
Why?
|
| Chronic Pain | 2 | 2019 | 110 | 0.610 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2017 | 22 | 0.600 |
Why?
|
| Corticotropin-Releasing Hormone | 5 | 2011 | 79 | 0.600 |
Why?
|
| Adolescent | 23 | 2020 | 8903 | 0.580 |
Why?
|
| Substance Abuse Detection | 2 | 2023 | 66 | 0.580 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 77 | 0.570 |
Why?
|
| Depression | 4 | 2017 | 942 | 0.560 |
Why?
|
| Precision Medicine | 1 | 2017 | 111 | 0.550 |
Why?
|
| Opiate Substitution Treatment | 3 | 2015 | 57 | 0.550 |
Why?
|
| Smoking | 4 | 2016 | 1449 | 0.550 |
Why?
|
| Alcohol-Related Disorders | 1 | 2017 | 95 | 0.550 |
Why?
|
| Life Change Events | 5 | 2013 | 223 | 0.540 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 105 | 0.540 |
Why?
|
| Secondary Prevention | 5 | 2019 | 291 | 0.530 |
Why?
|
| Family Characteristics | 1 | 2015 | 44 | 0.520 |
Why?
|
| Combined Modality Therapy | 6 | 2021 | 951 | 0.500 |
Why?
|
| Depressive Disorder | 1 | 2018 | 621 | 0.500 |
Why?
|
| Program Development | 2 | 2017 | 240 | 0.490 |
Why?
|
| Saliva | 5 | 2022 | 142 | 0.480 |
Why?
|
| Social Support | 2 | 2016 | 423 | 0.480 |
Why?
|
| Education | 2 | 2011 | 83 | 0.470 |
Why?
|
| Sertraline | 4 | 2012 | 62 | 0.470 |
Why?
|
| Surveys and Questionnaires | 9 | 2022 | 2798 | 0.460 |
Why?
|
| Administration, Intranasal | 4 | 2022 | 88 | 0.460 |
Why?
|
| Pain Management | 2 | 2014 | 186 | 0.450 |
Why?
|
| Sleep Wake Disorders | 1 | 2014 | 94 | 0.450 |
Why?
|
| Perception | 1 | 2014 | 189 | 0.450 |
Why?
|
| Mood Disorders | 2 | 2013 | 132 | 0.430 |
Why?
|
| Anxiety Disorders | 3 | 2022 | 426 | 0.420 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2012 | 20 | 0.420 |
Why?
|
| Case-Control Studies | 7 | 2015 | 1548 | 0.400 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 424 | 0.380 |
Why?
|
| Motivation | 6 | 2021 | 561 | 0.380 |
Why?
|
| Galvanic Skin Response | 4 | 2018 | 67 | 0.370 |
Why?
|
| Blood Pressure | 3 | 2015 | 1447 | 0.370 |
Why?
|
| Socioeconomic Factors | 6 | 2020 | 955 | 0.370 |
Why?
|
| Cocaine | 3 | 2023 | 555 | 0.360 |
Why?
|
| Self Report | 4 | 2023 | 370 | 0.350 |
Why?
|
| Research | 1 | 2011 | 214 | 0.350 |
Why?
|
| Child Abuse | 5 | 2010 | 186 | 0.350 |
Why?
|
| Oxytocics | 2 | 2019 | 14 | 0.340 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 135 | 0.340 |
Why?
|
| Couples Therapy | 2 | 2019 | 10 | 0.330 |
Why?
|
| Brain | 6 | 2021 | 2175 | 0.330 |
Why?
|
| Patient Care | 1 | 2009 | 61 | 0.330 |
Why?
|
| Telemedicine | 1 | 2017 | 699 | 0.330 |
Why?
|
| Aged | 9 | 2020 | 14842 | 0.310 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 2264 | 0.310 |
Why?
|
| Fellowships and Scholarships | 3 | 2022 | 127 | 0.310 |
Why?
|
| Extinction, Psychological | 3 | 2023 | 240 | 0.290 |
Why?
|
| Age Factors | 7 | 2020 | 1860 | 0.270 |
Why?
|
| Health Personnel | 1 | 2009 | 286 | 0.270 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 442 | 0.260 |
Why?
|
| Child | 11 | 2020 | 6400 | 0.260 |
Why?
|
| Time Factors | 6 | 2017 | 4655 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 2222 | 0.260 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2017 | 109 | 0.250 |
Why?
|
| Patient Preference | 2 | 2015 | 57 | 0.240 |
Why?
|
| South Carolina | 4 | 2016 | 2750 | 0.240 |
Why?
|
| Interpersonal Relations | 4 | 2019 | 209 | 0.230 |
Why?
|
| Cold Temperature | 4 | 2006 | 90 | 0.230 |
Why?
|
| Substance Abuse Treatment Centers | 3 | 2015 | 71 | 0.220 |
Why?
|
| Survival Analysis | 2 | 2018 | 714 | 0.220 |
Why?
|
| Prevalence | 5 | 2020 | 1609 | 0.220 |
Why?
|
| Analysis of Variance | 6 | 2013 | 1039 | 0.220 |
Why?
|
| Biomedical Research | 2 | 2017 | 310 | 0.210 |
Why?
|
| Linguistics | 1 | 2022 | 10 | 0.210 |
Why?
|
| Tranquilizing Agents | 1 | 2021 | 7 | 0.210 |
Why?
|
| Expert Testimony | 1 | 2021 | 47 | 0.210 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2022 | 88 | 0.200 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2022 | 61 | 0.200 |
Why?
|
| Child Abuse, Sexual | 2 | 2003 | 150 | 0.200 |
Why?
|
| Fear | 1 | 2023 | 239 | 0.200 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 378 | 0.200 |
Why?
|
| Students | 1 | 2003 | 233 | 0.200 |
Why?
|
| Cannabis | 1 | 2023 | 115 | 0.200 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2020 | 8 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2021 | 141 | 0.190 |
Why?
|
| Neuroimaging | 2 | 2019 | 122 | 0.190 |
Why?
|
| Schizophrenia | 1 | 2022 | 206 | 0.190 |
Why?
|
| Students, Medical | 2 | 2014 | 210 | 0.180 |
Why?
|
| Age of Onset | 3 | 2011 | 188 | 0.180 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 260 | 0.180 |
Why?
|
| Bipolar Disorder | 1 | 2022 | 307 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2022 | 435 | 0.170 |
Why?
|
| Acute Pain | 1 | 2019 | 35 | 0.170 |
Why?
|
| Social Responsibility | 1 | 1998 | 39 | 0.170 |
Why?
|
| Psychotropic Drugs | 1 | 2018 | 83 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 766 | 0.160 |
Why?
|
| Functional Neuroimaging | 1 | 2018 | 82 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2018 | 107 | 0.160 |
Why?
|
| Negotiating | 1 | 2017 | 18 | 0.160 |
Why?
|
| Unemployment | 2 | 2015 | 18 | 0.160 |
Why?
|
| Pancreatitis | 1 | 2019 | 279 | 0.150 |
Why?
|
| Nerve Net | 1 | 2018 | 180 | 0.140 |
Why?
|
| Veterans Health | 1 | 2017 | 61 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 791 | 0.140 |
Why?
|
| Marijuana Abuse | 2 | 2011 | 251 | 0.140 |
Why?
|
| Ambulatory Care | 3 | 2008 | 339 | 0.140 |
Why?
|
| Antioxidants | 1 | 2018 | 304 | 0.140 |
Why?
|
| Preventive Psychiatry | 1 | 2015 | 3 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3256 | 0.140 |
Why?
|
| Parents | 1 | 1998 | 309 | 0.140 |
Why?
|
| Dehydroepiandrosterone | 1 | 2015 | 29 | 0.140 |
Why?
|
| Mental Health | 1 | 2018 | 278 | 0.140 |
Why?
|
| Adaptation, Psychological | 3 | 2021 | 447 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 737 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2014 | 35 | 0.130 |
Why?
|
| Community Mental Health Services | 1 | 2015 | 65 | 0.130 |
Why?
|
| Actigraphy | 1 | 2014 | 28 | 0.120 |
Why?
|
| Health Surveys | 1 | 2016 | 488 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2015 | 185 | 0.120 |
Why?
|
| Career Choice | 2 | 2014 | 98 | 0.120 |
Why?
|
| Gulf War | 1 | 2013 | 22 | 0.120 |
Why?
|
| Self Care | 1 | 2016 | 252 | 0.120 |
Why?
|
| Health Policy | 1 | 2015 | 221 | 0.120 |
Why?
|
| Employment | 2 | 2011 | 154 | 0.120 |
Why?
|
| Afghan Campaign 2001- | 1 | 2013 | 78 | 0.120 |
Why?
|
| Arousal | 2 | 2011 | 168 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2015 | 307 | 0.110 |
Why?
|
| Interview, Psychological | 1 | 2013 | 113 | 0.110 |
Why?
|
| Personality Inventory | 3 | 2009 | 196 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 546 | 0.110 |
Why?
|
| Quality of Life | 2 | 2020 | 1515 | 0.100 |
Why?
|
| Recurrence | 3 | 2009 | 948 | 0.100 |
Why?
|
| Risk Factors | 5 | 2010 | 5719 | 0.100 |
Why?
|
| Rehabilitation, Vocational | 1 | 2011 | 14 | 0.100 |
Why?
|
| Alcohol Deterrents | 1 | 2012 | 86 | 0.100 |
Why?
|
| Social Environment | 2 | 2010 | 182 | 0.100 |
Why?
|
| Crime Victims | 2 | 2005 | 286 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 2 | 2022 | 201 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 216 | 0.090 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2010 | 14 | 0.090 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2010 | 52 | 0.090 |
Why?
|
| Neurosecretory Systems | 1 | 2009 | 21 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 756 | 0.090 |
Why?
|
| Pain Clinics | 1 | 2009 | 8 | 0.090 |
Why?
|
| Yohimbine | 1 | 2009 | 41 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2011 | 368 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 334 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 60 | 0.090 |
Why?
|
| Research Subjects | 1 | 2009 | 45 | 0.090 |
Why?
|
| Heroin | 1 | 2009 | 49 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2015 | 2453 | 0.090 |
Why?
|
| Cycloserine | 1 | 2009 | 30 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2013 | 2356 | 0.080 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2009 | 92 | 0.080 |
Why?
|
| Self-Injurious Behavior | 1 | 2009 | 31 | 0.080 |
Why?
|
| Infant | 1 | 2015 | 2891 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2015 | 3185 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 536 | 0.080 |
Why?
|
| Tobacco Use Disorder | 1 | 2013 | 432 | 0.080 |
Why?
|
| Residential Treatment | 1 | 2008 | 24 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2009 | 239 | 0.080 |
Why?
|
| Manuals as Topic | 1 | 2007 | 8 | 0.080 |
Why?
|
| Remote Consultation | 1 | 2008 | 50 | 0.080 |
Why?
|
| Mathematics | 1 | 2007 | 83 | 0.080 |
Why?
|
| Telephone | 1 | 2008 | 160 | 0.070 |
Why?
|
| Reward | 1 | 2008 | 201 | 0.070 |
Why?
|
| Touch | 1 | 2006 | 25 | 0.070 |
Why?
|
| Task Performance and Analysis | 1 | 2007 | 150 | 0.070 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2009 | 266 | 0.070 |
Why?
|
| Social Behavior | 1 | 2007 | 164 | 0.070 |
Why?
|
| Placebos | 1 | 2006 | 195 | 0.070 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2007 | 91 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 929 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2011 | 657 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1465 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2009 | 3702 | 0.070 |
Why?
|
| Narcotic Antagonists | 1 | 2006 | 184 | 0.060 |
Why?
|
| Affect | 1 | 2006 | 218 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 213 | 0.060 |
Why?
|
| Naltrexone | 1 | 2006 | 195 | 0.060 |
Why?
|
| Counseling | 3 | 2012 | 279 | 0.060 |
Why?
|
| Singapore | 1 | 2003 | 7 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2003 | 55 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1753 | 0.060 |
Why?
|
| Research Design | 1 | 2008 | 729 | 0.060 |
Why?
|
| Georgia | 1 | 2003 | 161 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 467 | 0.060 |
Why?
|
| Marital Status | 1 | 2003 | 65 | 0.060 |
Why?
|
| Women's Health | 1 | 2003 | 148 | 0.060 |
Why?
|
| Universities | 1 | 2003 | 191 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2003 | 117 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2023 | 96 | 0.050 |
Why?
|
| Aggression | 1 | 2022 | 98 | 0.050 |
Why?
|
| Texas | 1 | 2021 | 92 | 0.050 |
Why?
|
| Syndrome | 1 | 2021 | 255 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2020 | 249 | 0.050 |
Why?
|
| Australia | 1 | 2020 | 235 | 0.050 |
Why?
|
| Suicidal Ideation | 1 | 2021 | 106 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 42 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 58 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 2019 | 80 | 0.040 |
Why?
|
| Psychometrics | 1 | 2022 | 514 | 0.040 |
Why?
|
| Morphine | 1 | 2019 | 76 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 196 | 0.040 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2018 | 27 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2013 | 652 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2018 | 105 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 346 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 442 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 159 | 0.040 |
Why?
|
| New York | 1 | 2017 | 223 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2020 | 326 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2077 | 0.030 |
Why?
|
| Ethanol | 1 | 2022 | 892 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1593 | 0.030 |
Why?
|
| Toxocariasis | 1 | 1994 | 1 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2000 | 659 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 718 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 429 | 0.030 |
Why?
|
| Drug Storage | 1 | 2013 | 16 | 0.030 |
Why?
|
| Dental Clinics | 1 | 2013 | 9 | 0.030 |
Why?
|
| Refuse Disposal | 1 | 2013 | 22 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 639 | 0.030 |
Why?
|
| HIV Infections | 1 | 2001 | 775 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 458 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 420 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 445 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 1329 | 0.030 |
Why?
|
| Educational Status | 1 | 2011 | 273 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2010 | 96 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 390 | 0.020 |
Why?
|
| Curriculum | 1 | 2014 | 575 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 133 | 0.020 |
Why?
|
| Animals | 3 | 2018 | 20877 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 334 | 0.020 |
Why?
|
| Feeding and Eating Disorders | 1 | 2010 | 106 | 0.020 |
Why?
|
| Self Administration | 1 | 2009 | 419 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2009 | 241 | 0.020 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2007 | 19 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2009 | 303 | 0.020 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2007 | 28 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 563 | 0.020 |
Why?
|
| Anxiety | 1 | 2010 | 422 | 0.020 |
Why?
|
| Aftercare | 1 | 2008 | 114 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 319 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2009 | 470 | 0.020 |
Why?
|
| Immersion | 1 | 2006 | 10 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 2006 | 29 | 0.020 |
Why?
|
| Self Medication | 1 | 2006 | 25 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 2006 | 46 | 0.020 |
Why?
|
| Thermosensing | 1 | 2006 | 10 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2006 | 78 | 0.020 |
Why?
|
| Methamphetamine | 1 | 2007 | 132 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2008 | 294 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 402 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 218 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 579 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 2083 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2005 | 218 | 0.020 |
Why?
|
| Defense Mechanisms | 1 | 2003 | 14 | 0.010 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2003 | 53 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 2550 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 5300 | 0.010 |
Why?
|
| Prejudice | 1 | 2001 | 37 | 0.010 |
Why?
|
| Domestic Violence | 1 | 2001 | 36 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1054 | 0.010 |
Why?
|
| Toxocara canis | 1 | 1994 | 1 | 0.010 |
Why?
|
| Chile | 1 | 1994 | 17 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 1994 | 41 | 0.010 |
Why?
|
| Family Health | 1 | 1994 | 83 | 0.010 |
Why?
|